Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals (Nasdaq: GLMD) received a Nasdaq notice dated January 29, 2026, informing the company that its ordinary shares are below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Summary

Galmed Pharmaceuticals (Nasdaq: GLMD) received a Nasdaq notice dated January 29, 2026, informing the company that its ordinary shares are below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2).

The company has a 180-calendar-day compliance period from January 29, 2026, through July 28, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days. Trading of GLMD shares continues on the Nasdaq Capital Market during the cure period, and failure to regain compliance could lead to delisting procedures.

Positive

• Company granted a 180-calendar-day Nasdaq cure period
• Shares continue to trade on Nasdaq during the cure period

Negative

• Ordinary shares are below the required $1.00 minimum bid price
• Risk of delisting if $1.00 bid-price compliance not achieved by July 28, 2026

Argus Feb 2 session

-6.28% close to close Open Argus

Details

News Market Reaction – GLMD

On Feb 2, the first trading day after this news, GLMD closed 6.28% below the previous close.

Data tracked by StockTitan Argus for the Feb 2 session.

Key Figures

Nasdaq minimum bid price: $1.00 per share Initial compliance period: 180 calendar days Compliance window start: January 29, 2026 +5 more

Nasdaq minimum bid price

$1.00 per share

Listing Rule 5550(a)(2) requirement

Initial compliance period

180 calendar days

Nasdaq bid-price cure window

Compliance window start

January 29, 2026

Start of Nasdaq cure period

Compliance window end

July 28, 2026

End of initial Nasdaq cure period

Required streak

10 consecutive business days

Minimum period bid must be ≥ $1

Share price pre-notice

$0.75

Compared with $1.00 Nasdaq threshold

Price change

-7.59%

24h move prior to article publication

52-week range

$0.7311 – $3.50

Pre-news trading range

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   Conference abstract

   24h Move

   +8.0%

   Late-breaking HEP-DART abstract for Aramchol with oncology-focused preclinical data.

2. Dec 04

   IP / patents

   24h Move

   +6.5%

   New use patent grant expanding Aramchol combination IP and extending protection.

3. Dec 01

   Corporate update

   24h Move

   +3.7%

   CEO letter outlining cash position, burn rate, and planned trials for Aramchol.

4. Nov 26

   Earnings update

   24h Move

   +12.4%

   Q3 2025 results plus business update and equity-raising disclosure supporting runway.

5. Nov 18

   Clinical data

   24h Move

   +3.8%

   AM-001 Phase 1 bioavailability data showing higher exposure for Aramchol meglumine.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price, listing rule 5550(a)(2), nasdaq capital market, marketing authorization, +4 more

8 terms

minimum bid price regulatory

"not in compliance with the minimum bid price requirement for continued listing"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

listing rule 5550(a)(2) regulatory

"requirement for continued listing set forth in Listing Rule 5550(a)(2)"

Listing Rule 5550(a)(2) is a Nasdaq listing standard that sets a minimum share-price requirement for securities to be listed or to remain listed on the Nasdaq Capital Market. It matters to investors because falling below that minimum can trigger delisting reviews or increased volatility, much like a safety bar on a ride — if a stock can’t meet the height requirement, it risks being removed from the exchange, which can reduce liquidity and access for buyers and sellers.

nasdaq capital market regulatory

"initial listing standards for The Nasdaq Capital Market, with the exception"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

marketing authorization regulatory

"including but not limited to acceptance of an application for marketing authorization"

An official government approval that allows a drug, vaccine, or medical device to be sold and promoted in a specific country or region. Think of it as a safety and effectiveness passport issued after regulators review the product’s tests and manufacturing; for investors, receiving this authorization typically unlocks sales, revenue potential, and lower regulatory risk, while delays or denials can substantially affect a company’s value and timeline.

form 6-k regulatory

"Report of Foreign Private Issuer on Form 6-K filed with the Securities"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

form 20-f regulatory

"Annual Report on Form 20-F for the year ended December 31, 2024"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

digital asset management strategy financial

"risks relating to our digital asset management strategy, including the highly"

A digital asset management strategy is a company’s plan for organizing, storing, protecting and using its digital items—such as documents, images, videos, code and data—so they can be found and used reliably. Like a well‑labeled filing system, it reduces wasted time, lowers legal or security risks, and makes it easier to monetize or reuse content; investors watch it because poor practices can harm productivity, brand value and compliance, while strong practices can boost efficiency and revenue.

cryptocurrencies financial

"highly volatile nature of the price of cryptocurrencies and other digital assets"

Cryptocurrencies are digital forms of money or tokens secured by cryptography and recorded on shared digital ledgers, like a public spreadsheet that many computers maintain together. They matter to investors because their market values can swing widely, can act as speculative investments or portfolio diversifiers, and are exposed to unique risks such as regulatory changes, cybersecurity threats, and adoption shifts that can quickly affect prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

 

Further, the Nasdaq Listing Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from January 29, 2026, or until July 28, 2026, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period.

If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.

The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Galmed's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "GLMD".

About Galmed Pharmaceuticals Ltd.

We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver diseases, and continue to actively advance Aramchol for the treatment of combination therapy for NASH. We are also seeking to develop Aramchol for certain oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.

Forward-Looking Statements

Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and timing and effect thereof. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential synergistic effect of Aramchol, Stivarga^® and Metformin as a new fixed-dose combination treatment, the expected timing of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel, risks relating to our digital asset management strategy, including the highly volatile nature of the price of cryptocurrencies and other digital assets, the risk that our share price may be highly correlated to the price of the cryptocurrencies and other digital assets that we may hold, risks related to increased competition in the industries in which we do and will operate, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding cryptocurrencies and other digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes and those risks and uncertainties identified in Exhibit 99.2 to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on August 25, 2025. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 2, 2025 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Logo - https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-announces-receipt-of-nasdaq-minimum-bid-price-notification-302674968.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed (GLMD) announce about Nasdaq compliance on January 30, 2026?

Galmed said it received a Nasdaq notice for failing the $1.00 minimum bid requirement. According to the company, Nasdaq gave a 180-calendar-day cure period from January 29, 2026, through July 28, 2026, to regain compliance by meeting the $1.00 bid-price test.

How can GLMD regain compliance with Nasdaq's minimum bid price rule?

GLMD can regain compliance by having a closing bid of at least $1.00 for ten consecutive business days. According to the company, achieving that 10-day $1.00 close during the 180-day period triggers written confirmation of compliance from Nasdaq.

Does the Nasdaq notice affect trading of Galmed ordinary shares (GLMD)?

No, the notice has no immediate effect on trading of GLMD shares. According to the company, ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "GLMD" during the cure period.

What happens if Galmed (GLMD) does not regain compliance by July 28, 2026?

If GLMD fails to regain compliance by the deadline, Nasdaq may notify the company that its shares are subject to delisting. According to the company, an additional compliance period may be available if other listing standards are met except the bid-price requirement.

When is the compliance period for Galmed (GLMD) to meet Nasdaq's $1.00 bid requirement?

The compliance window runs 180 calendar days from January 29, 2026, to July 28, 2026. According to the company, the period allows GLMD to reach the required $1.00 closing bid for ten consecutive business days to cure the deficiency.